Drug profile · INN
lubiprostone
LUBIPROSTONE
lubiprostone (LUBIPROSTONE) is a chloride channel protein 2 opener. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — lubiprostone
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 16
- Data quality
- 0.89
Quick answer
lubiprostone (LUBIPROSTONE) is a chloride channel protein 2 opener. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Chloride channel protein 2 opener
Primary target: Chloride channel protein 2
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Frequently asked questions
What is lubiprostone?
lubiprostone (LUBIPROSTONE) is a chloride channel protein 2 opener. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for lubiprostone?
LUBIPROSTONE is a marketed brand name for lubiprostone. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of lubiprostone?
lubiprostone has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.